630-580-1088 sales@ambeed.com
Structure Search

List Search MOL Search Structure Search

0
Chemistry
Asymmetric Synthesis >>Chiral Building BlocksChiral Catalysts, Chiral Ligands and Chiral ReagentsChiral Resolution ReagentsBoronic acids/esters >>Aliphatic BoronsAromatic BoronsOther BoronsOxaborolesCatalysis Chemistry >>Achiral Crown LigandsC-H ActivationCarbon-Donor LigandsChiral Carbon LigandsChiral Crown LigandsChiral Olefin LigandsCross-CouplingCross-Coupling Using Transition Metal CatalystsDACH or Trost LigandsChemical Biology >>Conjugation Chemistry
GlycoscienceLinkers and CrosslinkersNucleic Acid ChemistryPEGylationPeptide ChemistryPhotolabile Protecting GroupHeterocyclic Building Blocks >>AcridinesAliphatic HeterocyclesAromatic HeterocyclesAzetidinesBenzimidazolesBenzisoxazolesBenzodioxansBenzofuransBenzothiazolesInorganic reagents >>Inorganic ReagentOrganic Building Blocks >>Acid AnhydridesAcyl Chlorides
AlcoholsAldehydesAliphatic Chain HydrocarbonsAliphatic Cyclic HydrocarbonsAlkenesAlkylsAlkynesOrganometallic Reagents >>Grignard ReagentsOrganoarsenicOrganobismuthOrganoboronOrganogermaniumOrganolithiumOrganomercuryOrganosiliconOrganotinSpecialty Synthesis >>Enzyme-Mediated SynthesisFluorous SynthesisIonic Liquids
Solid Supported SynthesisStains and Dyes >>Acid DyesAzoic DyesBasic DyesDirect DyesDisperse DyesDye IntermediatesMordant DyesOil DyesOther Stains and DyesSynthetic Reagents >>Acids and BasesC-C Bond FormationC-X Bond Formation (Halogen)C-X Bond Formation (Non-Halogen)Chelation and Complexation CompoundsCondensation AgentsCouplingDehydrating ReagentsFluorination Reagent
Pharmaceutical Intermediates
Analgesics >>BenzhydrocodoneBicifadineCapsaicinCelecoxibDebio-0827DexamethasoneElagolix SodiumEsketamine HydrochlorideIbuprofen SodiumAnesthetics >>CiprofolEsketamine HydrochlorideFospropofol Fospropofol DisodiumLevobupivacaine RemimazolamRemimazolam BesilateRemimazolam BesylateRopivacaineAnti-Addiction Agents >>Kakonein
Lofexidine HydrochlorideVarenicline Anti-inflammatory Agents >>ApremilastAsunaprevirATB-346 RelatedBalsalazide BaricitinibBencycloquidium BromideBudesonideCefiderocol Sulfate TosylateCeftaroline Fosamil AcetateAntibacterials >>AFN-1252 RelatedAlatrofloxacin Bedaquiline FumarateBesifloxacin BrilacidinCaspofungin AcetateCefiderocol Sulfate TosylateCefilavancinCeftaroline Fosamil
Anticonvulsants >>BrivaracetamCannabidiolEscitalopram OxalateEslicarbazepine Acetate RelatedFosphenytoinGabapentin EnacarbilJNJ-10234094LacosamideLevetiracetam RelatedAntidementia Agents >>Azeliragon RelatedDavunetideDonepezil HydrochlorideDonepezil RelatedEnsaculinFlorbetaben Flortaucipir F 18Flutemetamol IdalopirdineAntidepressants >>4-Chlorokynurenine
AgomelatineAgomelatine RelatedAllopregnanolone RelatedAmibegronAmitifadineAripiprazole RelatedBasimglurantBefloxatoneAntiemetics >>AprepitantAprepitant RelatedDolasetron RelatedDolasetron Mesylate HydrateFosaprepitant DimeglumineFosaprepitant RelatedOlanzapinePalonosetron RelatedPalonosetron HydrochlorideAntifungals >>Anidulafungin RelatedCabotegravirMore >>
Inhibitors/Agonists
ADC >>ADC AntibodyADC LinkerADC Linker with PayloadADC ToxinAntibody-Drug Conjugates (ADCs)Drug-Linker Conjugates for ADCAngiogenesis >>ALKBcr-AblBTKEGFRFAKFGFRFLT3HER2HIFAnti-infection >>3CLproAntibacterialAntibioticAntifungal
AntiparasiticAntiprotozoalAntiviralArenavirusBVDVApoptosis >>Apoptosis InducerBcl-2Bcl-6BRKc-Mycc-RETC/EBPCARDCaspaseAutophagy >>Atg4ATG4BATTECsAUTACsAutophagyBeclin1
FKBPLC3LRRK2Biochemical Reagent >>Cell Cycle >>AntifolateAPCAurora KinaseBUBCasein KinaseCdc25CDKChkCRISPR/Cas9Cytoskeleton >>ActinArp2/3 ComplexCYTHCytoplasmic DyneinDynaminFAKMore >>
Material Science
Aggregation-Induced Emission >>Other AIE BlocksTetraphenylethylene SeriesCOFs Linkers >>Aldehyde COFs LinkersAlkynyl COFs LinkersAmine COFs LinkersBoric COFs LinkersCyano COFs LinkersMultifunctional COFs linkersOther COFs linkersTriptycene SeriesElectronic Materials >>Battery MaterialsDye-Sensitized Solar Cell (DSSC) MaterialsElectronic MaterialLiquid Crystal (LC) MaterialsMolecular ConductorsOrganic Light-Emitting Diode (OLED) MaterialsOrganic Solar Cell (OPV) MaterialsOrganic Transistor (OFET) MaterialsPerovskite Solar Cell (PSC) MaterialsMagnetic Materials >>Magnetic Ionic LiquidsMagnetic MaterialMagnetic Metal Complexes
Organic Radicals Material Chemical Compounds >>Ligands for Functional Metal ComplexesLiquid Crystal (LC) Building BlocksPhthalocyanine Building BlocksPolymer and Macromolecule Semiconductor Building BlocksSmall Molecule Semiconductor Building BlocksSolubility Enhancing Reagents Supramolecular Host Materials MOF Ligands >>Carboxylic Acid MOF LigandsCarboxylic Acid Nitrogen-Containing Mixed MOF LigandsNitrogen-Containing MOF LigandsOther MOF LigandsNanomaterials >>Carbon NanomaterialsCeramic MembranesDendrimersGold NanoparticlesIron Oxide NanoparticlesMaterials by ApplicationMesoporous MaterialsMetals and Metal AlloysNano Minerals: NanoclaysOLED Materials >>Dopant
HostHTMOLED IntermediatesOther OLED related materialsOptical Materials >>Coumarin DyesCyanine and Squarylium DyesDCM DyesDipyrromethene DyesFluorescence MaterialsFluorescent ProbesHeat and Pressure Sensitive DyesNear-Infrared (NIR) DyesOrganic Non-Linear Optical (NLO) MaterialsOrganic Pigments >>Organic PigmentOther Materials >>Mateial OtherPolymer Science >>MonomersPolymer AdditivesPolymerization ReagentsPolymersResins
Contact Us
Home Cart 0 Sign in  
Chemistry
Heterocyclic Building Blocks
Pyridines
tert-Butyl 1-(3-bromo-5-fluoropyridin-4-yl)piperidine-4-carboxylate
Chemistry
Heterocyclic Building Blocks
Organic Building Blocks
Pyridines
Piperidines Bromides Fluorinated Building Blocks Esters

[ CAS No. 1613193-36-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1613193-36-4
Chemical Structure| 1613193-36-4
Structure of 1613193-36-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1613193-36-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1613193-36-4 ]

SDS Specification
Alternatived Products of [ 1613193-36-4 ]

Product Details of [ 1613193-36-4 ]

CAS No. :1613193-36-4 MDL No. :MFCD29053446
Formula : C15H20BrFN2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 359.23 Pubchem ID :-
Synonyms :

Safety of [ 1613193-36-4 ]

Signal Word: Class:
Precautionary Statements: UN#:
Hazard Statements: Packing Group:

Application In Synthesis of [ 1613193-36-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1613193-36-4 ]

[ 1613193-36-4 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 892493-65-1 ]
  • [ 1613192-96-3 ]
  • [ 1613193-36-4 ]
YieldReaction ConditionsOperation in experiment
65% 3-bromo-4-chloro-5-fluoro-pyridine hydrochloride 18 (62 g, 251.1 mmol) was suspended in DCM (600 mL) and stirred. The mixture was cooled in an ice bath and sodium hydroxide (276.2 mL of 1 M, 276.2 mmol) was added slowly. The resulting mixture was stirred for 1 hour. The mixture was phase-separated. More DCM/water was added to aid phase separation. Some tarry particulates remained in the aqueous phase. The organic phase was washed with brine, dried (MgS04), filtered and concentrated. The residue was triturated with heptane. The heptane solution was filtered through a florsil pad, eluting with heptane. The filtrate was concentrated to an oil which solidified. This gave 41g of free base. [00384] A thoroughly stirred mixture of 3-bromo-4-chloro-5-fluoropyridine free base (55 g, 0.26 mol), potassium fluoride (31 g, 0.53 mol) and Me4NCl (5.8 g, 53 mmol) in DMSO (400 mL) was heated to 130°C for 2 hours. The reaction mixture was cooled to room temperature and <strong>[892493-65-1]tert-butyl piperidine-4-carboxylate hydrochloride</strong> 22 (66 g, 0.30 mol) and DIPEA (65 g, 0.50 mol) were added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated in vacuo. The residue was portioned between DCM/water. The organic layer was washed with water (3x), dried over Na2S04, and filtered over silica gel using DCM as eluent. The filtrated was evaporated to give tert-butyl l-(3-bromo-5- fluoropyridin-4-yl)piperidine-4-carboxylate 26 (61g, 65percent) as a light yellow solid; 1H NMR (500 MHz, DMSO-i/6) delta 8.47 (s, 1H), 8.41 (d, 1H), 3.39 - 3.36 (m, 2H), 3.12 (tt, 2H), 2.49 - 2.43 (m, 1H), 1.91 - 1.87 (m, 2H), 1.71 - 1.64 (m, 2H) and 1.43 (s, 9H); 19F NMR (500 MHz, DMSO-d6) delta -135.2; MS (ES+) 361.0.
Reference： [1]Patent: WO2014/89379,2014,A1 .Location in patent: Paragraph 00383; 00384
  • 2
  • [ 1211540-92-9 ]
  • [ 1613193-36-4 ]
Reference： [1]Patent: WO2014/89379,2014,A1
[2]Patent: WO2014/89379,2014,A1
[3]Patent: US2015/158872,2015,A1
  • 3
  • [ 1613192-96-3 ]
  • [ 138007-24-6 ]
  • [ 1613193-36-4 ]
YieldReaction ConditionsOperation in experiment
49% With sodium carbonate; In cyclohexanol; at 120℃; for 18h;Inert atmosphere; A 3L flange flask equipped with a thermometer, condensor, nitrogen line and overhead stirrer was heated at 40°C (external) then charged with cyclohexanol (750 mL), disodium carbonate (129.8 g, 1.225 mol), 3-bromo-4-chloro-5-fluoro-pyridine (Hydrochloric Acid 18) (137.5 g, 556.8 mmol) and <strong>[138007-24-6]ter<strong>[138007-24-6]t-butyl piperidine-4-carboxylate</strong></strong> (123.8 g, 668.2 mmol) rinsed in with cyclohexanol (350 mL). Mixture was heated to 120°C internal temperature overnight (18h). Reaction mixture was removed from hotplate and allowed to cool to room temperature. Water (687.5 mL) and EtOAc (687.5 mL) were added, stirred for 10 mins then transferred to separating funnel. Additional EtOAc (1.238 L) was added, mixed and aqueous phase was removed. Organic phase was further washed with water (687 mL), aqueous phase removed, organic layer collected. Aqueous phases were combined and back extracted with EtOAc (687.5 mL), aqueous layer removed and organic phase combined with other organics. Organics concentrated in vacuo (water bath temp = 60°C, vaccum down to 2 mBar) leaving a viscous brown oil. [00379] Oil was dissolved in 25percent EtO Ac/petrol then passed through a short silica pad, eluting with 25percent EtOAc/petrol until no more product came off. Filtrate was concentrated in vacuo to leave a brown oil, 127. lg. Product re-purified by ISCO companion (1.5Kg Silica, loaded in DCM, eluting 0 to 20percent EtO Ac/petrol), product fractions combined and concentrated in vacuo to leave desired product 26 as a pale yellow to cream solid, (98g, 49percent yield). 'H NMR (500 MHz, DMSO-d6) delta 8.47 (s, 1H), 8.41 (d, 1H), 3.39 - 3.36 (m, 2H), 3.12 (tt, 2H), 2.49 - 2.43 (m, 1H), 1.91 - 1.87 (m, 2H), 1.71 - 1.64 (m, 2H) and 1.43 (s, 9H). MS (ES+) 361.0.
49% With sodium carbonate; In cyclohexanol; at 40 - 120℃;Inert atmosphere; [0499] A 3 L flange flask equipped with a thermometer,condenser, nitrogen line and overhead stirrer was heated at40° C. (external) then charged with cyclohexanol (750 mL),disodium carbonate (129.8 g, 1.225 mol), 3-bromo-4-chloro-5-fluoro-pyridine (Hydrochloric Acid 18) (137.5 g, 556.8mmol) and <strong>[138007-24-6]ter<strong>[138007-24-6]t-butyl piperidine-4-carboxylate</strong></strong> (123.8 g,668.2 mmol) rinsed in with cyclohexanol (350 mL). Mixturewas heated to 120° C. internal temperature overnight (18 hr.).Reaction mixture was removed from hotplate and allowed tocool to room temperature. Water (687.5 mL) and EtOAc( 687.5 mL) were added, stirred for 10 mins then transferred toseparating funnel. Additional EtOAc (1.238 L) was added,mixed and aqueous phase was removed. Organic phase wasfurther washed with water ( 687 mL ), aqueous phase removed,organic layer collected. Aqueous phases were combined andback extracted with EtOAc (687.5 mL), aqueous layerremoved and organic phase combined with other organics.Organics concentrated in vacuo (water bath temp=60° C.,vacuum down to 2 mBar) leaving a viscous brown oil.[0500] Oil was dissolved in 25percent EtOAc/petrol then passedthrough a short silica pad, eluting with 25percent EtOAc/petroluntil no more product came off. Filtrate was concentrated invacuo to leave a brown oil, 127.1 g. Product re-purified byISCO companion (1.5 Kg Silica, loaded in DCM, eluting 0 to20percent EtOAc/petrol), product fractions combined and concentratedin vacuo to leave desired product 26 as a pale yellow tocream solid, (98 g, 49percent yield). 1 H NMR (500 MHz, DMSOd6)o 8.47 (s, lH), 8.41 (d, lH), 3.39-3.36 (m, 2H), 3.12 (tt,2H), 2.49-2.43 (m, lH), 1.91-1.87 (m, 2H), 1.71-1.64 (m, 2H)and 1.43 (s, 9H). MS (ES+) 361.0.
Reference： [1]Patent: WO2014/89379,2014,A1 .Location in patent: Paragraph 00378; 00379
[2]Patent: US2015/158872,2015,A1 .Location in patent: Paragraph 0498; 0499; 0500
  • 4
  • [ 1613193-36-4 ]
  • [ 1613191-99-3 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 4 steps 1.1: tris-(dibenzylideneacetone)dipalladium(0); 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; Benzophenone imine; caesium carbonate / 1,4-dioxane / 95 °C / Inert atmosphere 1.2: 0.5 h / 20 °C 2.1: pyridine / 95 °C / Inert atmosphere 3.1: hydrogenchloride / water; 1,4-dioxane / Inert atmosphere 4.1: N-[(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylene]-dimethyl-ammonium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / Inert atmosphere
Multi-step reaction with 5 steps 1.1: tris-(dibenzylideneacetone)dipalladium(0); 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; Benzophenone imine; caesium carbonate / 1,4-dioxane / 95 °C / Inert atmosphere 1.2: 0.5 h / 20 °C 2.1: pyridine / 95 °C / Inert atmosphere 3.1: triethylsilane / dichloromethane / 20 - 40 °C 4.1: hydrogenchloride / 1-methyl-pyrrolidin-2-one; 1,4-dioxane / 0.33 h / 20 °C 5.1: N-[(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylene]-dimethyl-ammonium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / Inert atmosphere
Multi-step reaction with 4 steps 1: Benzophenone imine; caesium carbonate; 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; tris-(dibenzylideneacetone)dipalladium(0) / 1,4-dioxane / 95 °C / Inert atmosphere 2: pyridine / 16 h / 90 - 100 °C 3: acetonitrile / 16 h / 75 - 80 °C 4: N-[(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylene]-dimethyl-ammonium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / Inert atmosphere
Multi-step reaction with 4 steps 1: Benzophenone imine; caesium carbonate; 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; tris-(dibenzylideneacetone)dipalladium(0) / 1,4-dioxane / 95 °C / Inert atmosphere 2: pyridine / 95 °C / Inert atmosphere 3: acetonitrile / 16 h / 75 - 80 °C 4: N-[(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylene]-dimethyl-ammonium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / Inert atmosphere

Reference： [1]Current Patent Assignee: VERTEX PHARMACEUTICALS (OLD) - WO2014/89379, 2014, A1
[2]Current Patent Assignee: VERTEX PHARMACEUTICALS (OLD) - WO2014/89379, 2014, A1
[3]Current Patent Assignee: VERTEX PHARMACEUTICALS (OLD) - US2015/158872, 2015, A1
[4]Current Patent Assignee: VERTEX PHARMACEUTICALS (OLD) - US2015/158872, 2015, A1
  • 5
  • [ 892493-65-1 ]
  • C5H2BrF2N [ No CAS ]
  • [ 1613193-36-4 ]
YieldReaction ConditionsOperation in experiment
61 g With N-ethyl-N,N-diisopropylamine; In dimethyl sulfoxide; at 20℃; [ 0505] 3 -bromo-4-chloro-5-fluoro-pyridine hydrochloride18 ( 62 g, 251.1 mmol) was suspended in DCM ( 600 mL) andstirred. The mixture was cooled in an ice bath and sodiumhydroxide (276.2 mL of 1 M, 276.2 mmol) was added slowly.The resulting mixture was stirred for 1 hour. The mixture wasphase-separated. More DCM/water was added to aid phaseseparation. Some tarry particulates remained in the aqueousphase. The organic phase was washed with brine, dried(MgS04 ), filtered and concentrated. The residue was trituratedwith heptane. The heptane solution was filtered througha florsil pad, eluting with heptane. The filtrate was concentratedto an oil which solidified. This gave 41 g offree base.[0506] A thoroughly stirred mixture of 3-bromo-4-chloro-5-fluoropyridine free base (55 g, 0.26 mol), potassium fluoride(31 g, 0.53mol)andMe4NCl (5.8 g, 53mmol)inDMSO( 400 mL) was heated to 130° C. for 2 hours. The reactionmixture was cooled to room temperature and <strong>[892493-65-1]tert-butyl piperidine-4-carboxylate hydrochloride</strong> 22 (66 g, 0.30 mol) andDIPEA (65 g, 0.50 mol) were added. The reaction mixturewas stirred at room temperature overnight. The solvent wasevaporated in vacuo. The residue was portioned betweenDCM/water. The organic layer was washed with water (3x),dried over Na2S04 , and filtered over silica gel using DCM aseluent. The filtrated was evaporated to give tert-butyl 1-(3-bromo-5-fluoropyridin-4-yl)piperidine-4-carboxylate 26 (61g, 65percent) as a light yellow solid; 1H NMR (500 MHz, DMSOd6)o 8.47 (s, lH), 8.41 (d, lH), 3.39-3.36 (m, 2H), 3.12 (tt,2H), 2.49-2.43 (m, lH), 1.91-1.87 (m, 2H), 1.71-1.64 (m, 2H)and 1.43 (s, 9H); 19FNMR (500 MHz, DMSO-d6) o-135.2;MS (ES+) 361.0.
Reference： [1]Patent: US2015/158872,2015,A1 .Location in patent: Paragraph 0503; 0506

Tags: 1613193-36-4 synthesis path| 1613193-36-4 SDS| 1613193-36-4 COA| 1613193-36-4 purity| 1613193-36-4 application| 1613193-36-4 NMR| 1613193-36-4 COA| 1613193-36-4 structure

Same Skeleton Products
Related Products
Categories
Chemistry
Heterocyclic Building Blocks
Pyridines
Chemistry
Heterocyclic Building Blocks
Piperidines
Chemistry
Organic Building Blocks
Bromides
Chemistry
Organic Building Blocks
Fluorinated Building Blocks
Chemistry
Organic Building Blocks
Esters
Historical Records